Oncolytic Virus Immunotherapy Market : Table of Content


  • Published On : Oct-2019 |
  • Pages : 119 Pages |
  • Format : Oncolytic Virus Immunotherapy Market Oncolytic Virus Immunotherapy Market Oncolytic Virus Immunotherapy Market Oncolytic Virus Immunotherapy Market

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

4. Key Inclusions

    4.1. Product Adoption / Usage Analysis 

    4.2. Product USPs / Features 

    4.3. Establishing Industry – Institutional Partnerships 

    4.4. Identifying Unique Delivery Methods for Oncolytic Virus Therapy

5. Global Oncolytic Virus Immunotherapy Market Demand (in Value or Size in US$ Mn) Analysis 2015-2018 and Forecast, 2019-2029

    5.1. Historical Market Value (US$ Mn) Analysis, 2015-2018

    5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Market Background

    6.1. Macro-Economic Factors

        6.1.1. Global GDP Growth Outlook

        6.1.2. Global Healthcare Industry Outlook

    6.2. Forecast Factors - Relevance & Impact

        6.2.1. Adoption of Oncolytic Virus Immunotherapy 

        6.2.2. Ongoing Clinical Trials

        6.2.3. Regulatory Imposition on Oncolytic Virus Immunotherapy

        6.2.4. Advancements in Oncolytic Virus Immunotherapy 

        6.2.5. Incremental R&D by Product-Based Companies

    6.3. Regulatory Scenario for GMP 

    6.4. Value Chain

    6.5. Market Dynamics

        6.5.1. Drivers

        6.5.2. Restraints

        6.5.3. Opportunity Analysis

7. Global Oncolytic Virus Immunotherapy Market - Venture Capital Financing

8. Global Oncolytic Virus Immunotherapy Market -Pipeline Analysis

9. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, by Indication 

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Indication, 2014 - 2018

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2019 - 2029

        9.3.1. Melanoma

    9.4. Market Attractiveness Analysis By Indication 

10. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, By End User

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Mn) Analysis By End User, 2014 - 2018

    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2019 - 2029

        10.3.1. Hospitals

        10.3.2. Specialty Clinics

        10.3.3. Cancer Research Institutes

    10.4. Market Attractiveness Analysis By End User

11. Global Oncolytic Virus Immunotherapy Market Analysis 2015-2018 and Forecast 2019-2029, by Region

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2018

    11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029

        11.3.1. North America

        11.3.2. Europe

    11.4. Market Attractiveness Analysis By Region

12. Competition Analysis

    12.1. Competition Dashboard

    12.2. Competition Deep Dive 

        12.2.1. BioVex, Inc. (Amgen, Inc.)

            12.2.1.1. Overview

            12.2.1.2. Product Portfolio

            12.2.1.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.1.4. Sales Footprint

            12.2.1.5. Strategy Overview

                12.2.1.5.1. Marketing Strategy

                12.2.1.5.2. Product Strategy

                12.2.1.5.3. Channel Strategy

        12.2.2. Cold Genesys, Inc. 

            12.2.2.1. Overview

            12.2.2.2. Product Portfolio

            12.2.2.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.2.4. Sales Footprint

            12.2.2.5. Strategy Overview

                12.2.2.5.1. Marketing Strategy

                12.2.2.5.2. Product Strategy

                12.2.2.5.3. Channel Strategy

        12.2.3. DNAtrix Therapeutics 

            12.2.3.1. Overview

            12.2.3.2. Product Portfolio

            12.2.3.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.3.4. Sales Footprint

            12.2.3.5. Strategy Overview

                12.2.3.5.1. Marketing Strategy

                12.2.3.5.2. Product Strategy

                12.2.3.5.3. Channel Strategy

        12.2.4. Genelux Corporation 

            12.2.4.1. Overview

            12.2.4.2. Product Portfolio

            12.2.4.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.4.4. Sales Footprint

            12.2.4.5. Strategy Overview

                12.2.4.5.1. Marketing Strategy

                12.2.4.5.2. Product Strategy

                12.2.4.5.3. Channel Strategy

        12.2.5. Lokon Pharma AB 

            12.2.5.1. Overview

            12.2.5.2. Product Portfolio

            12.2.5.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.5.4. Sales Footprint

            12.2.5.5. Strategy Overview

                12.2.5.5.1. Marketing Strategy

                12.2.5.5.2. Product Strategy

                12.2.5.5.3. Channel Strategy

        12.2.6. Oncolytics Biotech, Inc

            12.2.6.1. Overview

            12.2.6.2. Product Portfolio

            12.2.6.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.6.4. Sales Footprint

            12.2.6.5. Strategy Overview

                12.2.6.5.1. Marketing Strategy

                12.2.6.5.2. Product Strategy

                12.2.6.5.3. Channel Strategy

        12.2.7. ORYX GmbH & Co. KG 

            12.2.7.1. Overview

            12.2.7.2. Product Portfolio

            12.2.7.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.7.4. Sales Footprint

            12.2.7.5. Strategy Overview

                12.2.7.5.1. Marketing Strategy

                12.2.7.5.2. Product Strategy

                12.2.7.5.3. Channel Strategy

        12.2.8. PsiOxus Therapeutics 

            12.2.8.1. Overview

            12.2.8.2. Product Portfolio

            12.2.8.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.8.4. Sales Footprint

            12.2.8.5. Strategy Overview

                12.2.8.5.1. Marketing Strategy

                12.2.8.5.2. Product Strategy

                12.2.8.5.3. Channel Strategy

        12.2.9. SillaJen, Inc.

            12.2.9.1. Overview

            12.2.9.2. Product Portfolio

            12.2.9.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.9.4. Sales Footprint

            12.2.9.5. Strategy Overview

                12.2.9.5.1. Marketing Strategy

                12.2.9.5.2. Product Strategy

                12.2.9.5.3. Channel Strategy

        12.2.10. Sorrento Therapeutics, Inc. 

            12.2.10.1. Overview

            12.2.10.2. Product Portfolio

            12.2.10.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.10.4. Sales Footprint

            12.2.10.5. Strategy Overview

                12.2.10.5.1. Marketing Strategy

                12.2.10.5.2. Product Strategy

                12.2.10.5.3. Channel Strategy

        12.2.11. Takara Bio

            12.2.11.1. Overview

            12.2.11.2. Product Portfolio

            12.2.11.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.11.4. Sales Footprint

            12.2.11.5. Strategy Overview

                12.2.11.5.1. Marketing Strategy

                12.2.11.5.2. Product Strategy

                12.2.11.5.3. Channel Strategy

        12.2.12. Targovax ASA 

            12.2.12.1. Overview

            12.2.12.2. Product Portfolio

            12.2.12.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.12.4. Sales Footprint

            12.2.12.5. Strategy Overview

                12.2.12.5.1. Marketing Strategy

                12.2.12.5.2. Product Strategy

                12.2.12.5.3. Channel Strategy

        12.2.13. Transgene sa 

            12.2.13.1. Overview

            12.2.13.2. Product Portfolio

            12.2.13.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.13.4. Sales Footprint

            12.2.13.5. Strategy Overview

                12.2.13.5.1. Marketing Strategy

                12.2.13.5.2. Product Strategy

                12.2.13.5.3. Channel Strategy

        12.2.14. Turnstone Biologics 

            12.2.14.1. Overview

            12.2.14.2. Product Portfolio

            12.2.14.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.14.4. Sales Footprint

            12.2.14.5. Strategy Overview

                12.2.14.5.1. Marketing Strategy

                12.2.14.5.2. Product Strategy

                12.2.14.5.3. Channel Strategy

        12.2.15. VCN Biosciences 

            12.2.15.1. Overview

            12.2.15.2. Product Portfolio

            12.2.15.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.15.4. Sales Footprint

            12.2.15.5. Strategy Overview

                12.2.15.5.1. Marketing Strategy

                12.2.15.5.2. Product Strategy

                12.2.15.5.3. Channel Strategy

        12.2.16. Viralytics Ltd. (Merck & Co., Inc.) 

            12.2.16.1. Overview

            12.2.16.2. Product Portfolio

            12.2.16.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.16.4. Sales Footprint

            12.2.16.5. Strategy Overview

                12.2.16.5.1. Marketing Strategy

                12.2.16.5.2. Product Strategy

                12.2.16.5.3. Channel Strategy

        12.2.17. Vyriad

            12.2.17.1. Overview

            12.2.17.2. Product Portfolio

            12.2.17.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.17.4. Sales Footprint

            12.2.17.5. Strategy Overview

                12.2.17.5.1. Marketing Strategy

                12.2.17.5.2. Product Strategy

                12.2.17.5.3. Channel Strategy

        12.2.18. Shanghai Sunway Biotech

            12.2.18.1. Overview

            12.2.18.2. Product Portfolio

            12.2.18.3. Profitability by Market Segments (Product/Channel/Region)

            12.2.18.4. Sales Footprint

            12.2.18.5. Strategy Overview

                12.2.18.5.1. Marketing Strategy

                12.2.18.5.2. Product Strategy

                12.2.18.5.3. Channel Strategy

13. Assumptions and Acronyms Used

14. Research Methodology


List of Table

Table 01: Prevalence of Cancer in North America, 2017

Table 02: Prevalence of Cancer in Latin America, 2017

Table 03: Prevalence of Cancer in Asia Pacific, 2017

Table 04: Prevalence of Cancer in Europe, 2017

Table 05: Number of FDA Approvals (2010-2017)

Table 06: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 07: Expenditure on Health, (% of GDP), by Country, 2016 - 2021

Table 08: Funding by Research Areas 2017 (US $Millions)

Table 09: Funding by Research Areas 2017 (US $Millions)

Table 10: Estimated Number of Deaths for the Four Major Cancers by Sex and Age Group, 2017

Table 11: Global Oncolytic Virus Immunotherapy Market Deals and Collaborations (1/2) 

Table 12: Global Oncolytic Virus Immunotherapy Market Deals and Collaborations (2/2) 

Table 13: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (1/2) 

Table 14: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (2/2) 

Table 15: Oncolytic Virus Immunotherapy Market Top Oncolytic Virus Projects (3/3) 

Table 16: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (1/7)

Table 17: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (2/7)

Table 18: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (3/7)

Table 19: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (4/7)

Table 20: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (5/7)

Table 21: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (6/7)

Table 22: Oncolytic Virus Immunotherapy Pipeline Analysis By Virus Type (7/7)

Table 23: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Analysis 2015-2018 and Forecast 2019–2029, By End User

Table 24: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Analysis 2015-2018 and Forecast 2019–2029, By Region


List of Figures

Figure 01: Global Oncolytic Virus Immunotherapy Market Value Share By Indications (2019 E)

Figure 02: Global Oncolytic Virus Immunotherapy Market Value Share By End User (2019 E)

Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share By Regions (2019 E)

Figure 04: Number of FDA approved pharmaceuticals (2010-2017)

Figure 05: Global Healthcare Expenditure in US$ Tn (2013–2020)

Figure 06: New Cancer Drugs Approved Each Year

Figure 07: Estimates of National Expenditures for Cancer Care (In Billions Of Dollars) by Cancer Site and Year

Figure 08: Distribution of Industry sponsored Pipeline Projects for Oncolytic Virus Immunotherapy, by Indication

Figure 09: Distribution of Industry sponsored Pipeline Projects for Oncolytic Virus Immunotherapy By Phase

Figure 10: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Optimistic Scenario)

Figure 11: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Conservative Scenario)

Figure 12: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Opportunity Assessment 2019-2029 (Likely Scenario)

Figure 13: Global Oncolytic Virus Immunotherapy Market Value Analysis (US$ Mn), 2015-2018

Figure 14: Global Oncolytic Virus Immunotherapy Market Value Analysis (US$ Mn), 2019–2029

Figure 15: Global Oncolytic Virus Immunotherapy Market Absolute $ Opportunity, 2015-2018

Figure 16: Global Oncolytic Virus Immunotherapy Market Absolute $ Opportunity, 2019-2029

Figure 17: Global Oncolytic Virus Immunotherapy Market Analysis By End User –2019 & 2029

Figure 18: Global Oncolytic Virus Immunotherapy Market Y-o-Y Growth Projections by End User, 2019-2029

Figure 19: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, By End User

Figure 20: Global Oncolytic Virus Immunotherapy Market Share Analysis (%) By Region, 2019 & 2029

Figure 21: Global Oncolytic Virus Immunotherapy Market Y-o-Y Growth (%) By Region, 2019–2029

Figure 22: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, By Region

Oncolytic Virus Immunotherapy Market - Table of Content

Back To Top